Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (trading symbol: VIRI) on June 11, 2024. The filing addresses a critical corporate governance matter regarding the company's continued listing on the Nasdaq Capital Market. Note: The request metadata referenced "Dogwood Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Virios Therapeutics, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
- Compliance Exception Granted: On June 11, 2024, a Nasdaq Hearing Panel granted the company an exception until October 28, 2024, to regain compliance with the $1.00 minimum bid price requirement.
- Background: The company had previously failed to maintain the $1.00 minimum bid price for 30 consecutive business days starting November 7, 2023. An initial 180-day compliance period expired on April 30, 2024, triggering a potential delisting notice.
- Reverse Stock Split Contingency: The company prioritizes regaining compliance through other measures. However, if compliance is not achieved by October 11, 2024, the company will be required to undertake a reverse stock split to meet the October 28, 2024 deadline.
- Delisting Risk: Failure to regain compliance by October 28, 2024, will result in the delisting of the company's securities.
Guidance, Outlook, and Risks
Management Commentary: Management states there can be no assurance that a reverse stock split will ensure compliance with the minimum bid price requirement. The company also cannot predict the effect a reverse stock split would have on the market price of its common stock.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements. Key risks include the uncertainty of the Nasdaq Hearing Panel's decisions, the potential failure to regain compliance, and the possibility of delisting. Investors are directed to the 2023 Amended Annual Report on Form 10-K/A for a comprehensive list of risks.
Investor Verification Checklist
- Verify the current trading price of VIRI to assess the likelihood of meeting the $1.00 minimum bid price without a reverse stock split.
- Monitor company announcements between now and October 11, 2024, regarding the decision to implement a reverse stock split.
- Review the 2023 Amended Annual Report on Form 10-K/A for detailed financial health and operational risks not covered in this 8-K.
- Confirm the exact ratio of any potential reverse stock split if announced, as this will impact share count and liquidity.